Project Grant R44OD035390

Award Date 8/1/23
Completion Date 8/31/26
Dollars Obligated $1.3M
Funding Federal Agency
Office of the Director
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
This Project Grant award of $408,007 from the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to develop a technology called "glycosequencing" that uses next-generation sequencing (NGS) to sequence and quantify glycan structures. The project will first identify an optimal set of lectins, biochemically characterize them, and prepare lectin barcoding for NGS. It will also build a training dataset using recombinant proteins produced in glycoengineered Chinese...
The National Institute of General Medical Sciences (NIGMS) awarded a $382,500 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Texas A&M Engineering Experiment Station (Tees) for the project "Role of Membrane Dynamics in Cell Surface Glycan Recognition" from January 1, 2025 to December 31, 2029. The goal of this project is to investigate how the spatial organization of glycan ligands on cell membranes influences glycobiology processes, and to develop...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
This $350,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports the development and demonstration of a novel, enzyme-based, single-molecule protein sequencing system by Electronic Biosciences, Inc. The innovative platform aims to leverage enzymatic processing and advanced bioinformatics to enable scalable, multiplexed protein sequencing with high accuracy and throughput. During this Phase I...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $511,798 was awarded to Kilele Health Inc. on June 15, 2022 to develop continuous diagnostic monitoring platforms beyond glucose sensing. Unlike existing enzymatic glucose sensors, the company will utilize electrochemical aptamer sensors that can rapidly measure other molecules in the body with high specificity and sensitivity. The aim is to address limitations that have...
The National Institutes of Health National Institute of General Medical Sciences awarded a $903,000 Project Grant to The University of Toledo to develop new glycosylation methods for microbial glycan synthesis under the Biomedical Research and Research Training program (CFDA 93.859). Over a three-year period from September 2022 to August 2025, the University will create two new catalytic glycosylation methodologies - a cationic gold(I)-catalyzed glycosylation using glycosyl...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $456,000 to West Virginia University Research Corporation (WVURC) to develop an automated, microscale approach for customizing N-glycan standards. The project aims to adapt a capillary electrophoresis method to rapidly trim and rebuild glycan structures, integrating a thermally reversible nanogel to sustain enzyme-based...
The National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded a $450,000 Project Grant to the Texas A&M Engineering Experiment Station (Tees) to develop an injectable, grain-of-rice size glucose biosensor for continuous blood sugar monitoring. The key products or services to be provided under this 3-year grant include: Developing an injectable glucose biosensor comprised of a self-cleaning membrane and a near-infrared fluorescence...
The National Institute of General Medical Sciences (NIGMS) awarded a $358,862 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to GMJ Technologies, Inc., a minority-owned small business, to develop a microfluidic SDS depletion electrophoresis (SDE) interface. This interface will enable direct coupling of capillary electrophoresis with sodium dodecyl sulfate (CE-SDS) to mass spectrometry for improved characterization and quality control of monoclonal...
The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...

ENGINEERED PAN-SPECIFIC REAGENTS FOR N-GLYCAN DETECTION AND ENRICHMENT - PROJECT SUMMARY GLYCANS PLAY CRUCIAL ROLES IN NEARLY EVERY ASPECT OF BIOLOGICAL PROCESSES, AND THEIR DISTINCT PROPERTIES MAKE THEM APPEALING AS DISEASE BIOMARKER TARGETS. HOWEVER, DUE TO THEIR HIGHLY BRANCHED AND VARIABLY LINKED NATURE, GLYCANS POSE A CHALLENGE FOR DETECTION, PURIFICATION, AND STRUCTURAL ANALYSIS. ALTHOUGH ADVANCED ANALYTICAL TECHNIQUES AND INSTRUMENTATION HAVE BEEN DEVELOPED THAT TARGET GLYCANS, THERE IS STILL A GREAT NEED FOR REAGENTS WITH WELL-DEFINED CARBOHYDRATE SPECIFICITY AND HIGH AFFINITY THAT CAN BE USED TO INDEPENDENTLY INTERROGATE OR ENRICH CARBOHYDRATE SAMPLES PRIOR TO TRADITIONAL ANALYSES. LECTENZ BIO HAS BEEN ENGINEERING GLYCAN-PROCESSING ENZYMES AND GLYCAN-BINDING PROTEINS INTO HIGH-AFFINITY GLYCAN-SPECIFIC REAGENTS WITH TUNABLE PROPERTIES. THE FBS1 COMPONENT OF THE E3 UBIQUITIN LIGASE COMPLEX RECOGNIZES GLYCANS AS PART OF ITS BIOLOGICAL ROLE IN UBIQUITYLATION. IT IS THEREFORE A PROMISING PROTEIN FOR CONVERSION INTO A BINDING REAGENT FOR ASPARAGINE-LINKED GLYCANS (N-GLYCANS), WHICH WE WILL ACHIEVE BY EMPLOYING COMPUTATIONAL MODELING AND DIRECTED EVOLUTION. INITIAL STUDIES DEMONSTRATE THAT FBS1 CAN BE READILY EXPRESSED IN E. COLI, AND BINDS SPECIFICALLY TO N-GLYCOSYLATED PEPTIDES AND PROTEINS, AND NOT TO THE CORRESPONDING NON-GLYCOSYLATED PEPTIDES AND PROTEINS. HOWEVER, IT DOES DEMONSTRATE A PREFERENCE FOR CERTAIN N-GLYCAN STRUCTURES. A PAN-SPECIFIC N-GLYCAN BINDING REAGENT WOULD DIRECTLY ADDRESS THE URGENT NEED TO TOOLS TO HELP DETECT GLYCO- BIOMARKERS AND COULD IMMEDIATELY BENEFIT THE FIELD OF GLYCOMICS/GLYCOPROTEOMICS BY ENABLING SAMPLE PRE- ENRICHMENT. AFTER ENGINEERING AND OPTIMIZING THE PRODUCTION OF RECOMBINANT FBS1 AND ITS ENGINEERED VARIANTS, LECTENZ BIO WILL DEVELOP A SUITE OF KITS FOR ITS APPLICATION IN WESTERN BLOTTING, IMMUNOHISTOCHEMISTRY, ELISA, FLOW CYTOMETRY, AND AFFINITY CHROMATOGRAPHY.

Posted 7/20/23, 12:00 AM